Observing lung health in early COPD patients
Official title: Lung Health of Early Chronic Obstructive Pulmonary Disease: A Multi-center Cohort Study
Run by China-Japan Friendship Hospital · NCT05466396 · Data updated 2026-11-12
This study looks at how lung health changes in people with early COPD and how smoking and other factors might affect that decline.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 35 Years to 75 Years |
| Sex | All |
| Enrollment | 1550 (estimated) |
| Sponsor | China-Japan Friendship Hospital Academic / other |
| Locations | 2 sites (Beijing, Beijing Municipality and 1 other locations) |
| Status | Recruiting |
| Started | August 1, 2022 |
| Main results expected | December 30, 2026 |
| Study ends | December 31, 2027 |
| Registry record updated | February 17, 2025 |
| Trial ID | NCT05466396 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates for this study are individuals aged 35-75 with early COPD characterized by specific spirometry results.
✕Probably not a fit
Patients with other significant lung diseases or conditions that could affect lung function may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multi-center, prospective cohort study focuses on patients with early Chronic Obstructive Pulmonary Disease (COPD). It aims to investigate the decline in lung function and its relationship with smoking and other risk factors. The study will analyze various biomarkers and imaging results from chest CT scans to better understand lung health in these patients. By gathering data from multiple centers, the study seeks to provide a comprehensive view of early COPD progression.
Why it matters
Potential benefit: If successful, this study could lead to improved understanding and management of early COPD, potentially enhancing patient outcomes.
How similar studies have gone: While there have been studies on COPD, this specific approach focusing on early COPD and its risk factors is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Gender: male or female 2. Age: 35-75 years old 3. post-bronchodilator spirometry: FEV1/FVC \< 0.8 and FEV1%pred ≥80% Exclusion Criteria: 1. Other diseases may affect lung function, like lung cancer, bronchiectasis, interstitial lung disease or chest surgery. 2. BMI \> 35 kg/m2 3. Dementia or other severe neurological disease 4. Pregnancy 5. Conditions that contraindicated lung function test
Where it's running
-
China-Japan Friendship Hospital
Beijing, Beijing Municipality, China Recruiting -
Affiliated Hospital of Zunyi Medical University
Zunyi, Guizhou, China Recruiting
Study contacts
- Principal investigator: Ting Yang, M.D. — China-Japan Friendship Hospital
- Study coordinator: Ke Huang, M.D.
- Email: huangke_zryy@163.com
- Phone: +86-010-84206276
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
AERO-007: a inhaled LABA+LAMA combination for COPD through a nebulizer
This study tests whether a nebulized LABA+LAMA combination can improve lung function in adults with COPD.
-
Cognitive load and inhaler technique in COPD
This study tests whether adding a short memory task while using an inhaler makes COPD patients more likely to misuse their inhaler.
-
Balance training after pulmonary rehab for COPD to help steadiness and reduce falls
A COPD-focused balance training program called Sport4Steadiness is being tested to see if people with COPD will accept it and if the study processes work well.
-
Continuous vs High-Intensity Interval Exercise in COPD
This study tests whether continuous versus high-intensity interval exercise affects cerebral oxygenation in people with COPD.
-
Biomarker clues for COPD, IPF, and lung cancer
This study tests whether inflammation, immune, genetic, and epigenetic markers at enrollment can explain how COPD, IPF, or lung cancer present and behave, in order to see if these markers can predict outcomes over a year.
-
HRS-9821 Inhalation Suspension for COPD: Safety and Dose Finding in Adults
This study tests whether HRS-9821 inhalation can be safely taken and help people with moderate to severe COPD, and aims to find a reasonable dose.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.